ArticleInfection2009
A risk profile for invasive aspergillosis in liver transplant recipients.
Article in Infection, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Risk Factors of Invasive Fungal Infection in Recipients After Liver Transplantation: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Article
- Immunity to pathogenic mucosal C. albicans infections mediated by oral megakaryocytes activated by IL-17 and candidalysin.Mucosal immunology · 2024Article
- Invasive aspergillosis in liver transplant recipients, an infectious complication with low incidence but significant mortality.World journal of transplantation · 2023Article
- Epidemiology of Invasive Fungal Infections in Solid Organ Transplant Recipients: an Indian Perspective.Current fungal infection reports · 2022Review
- Does Post-Transplant Cytomegalovirus Increase the Risk of Invasive Aspergillosis in Solid Organ Transplant Recipients? A Systematic Review and Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2021Review
- Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response.BMC infectious diseases · 2021Article
- In Vitro Interaction between Isavuconazole and Tacrolimus, Cyclosporin A, or Sirolimus againstJournal of fungi (Basel, Switzerland) · 2020Article
- Platelets are critical for survival and tissue integrity during murine pulmonary Aspergillus fumigatus infection.PLoS pathogens · 2020Article
- Article
- Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response.Infection · 2019Review
- Menacing Mold: Recent Advances in Aspergillus Pathogenesis and Host Defense.Journal of molecular biology · 2019Review
- [Fungal infections].Der Internist · 2019Review
- Infectious Complications Following Solid Organ Transplantation.Critical care clinics · 2019Review
- Candida: Platelet Interaction and Platelet Activity in vitro.Journal of innate immunity · 2019Article
- Invasive Fungal Infections in Renal Transplant Recipients: Epidemiology and Risk Factors.Mycopathologia · 2015Article
- How to treat fungal infections in ICU patients.BMC infectious diseases · 2015Review
- Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome.Scientifica · 2013Review
- Aspergillus tracheobronchitis causing subtotal tracheal stenosis in a liver transplant recipient.Case reports in transplantation · 2013Article
- Emergency versus elective living-donor liver transplantation: a comparison of a single center analysis.Surgery today · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven the high incidence (1.5%-10%) of invasive aspergillosis (IA) after liver transplantation and the associated mortality, prophylaxis according to the patients' circumstances is a reasonable approach. The purpose of this investigation was to determine the effect and significance of risk factors for IA in a specialized transplantation center.
methodsWe collected data from patients who underwent liver transplantation at the Transplantation Center of the University Hospital Heidelberg (Germany) between December 2001 and December 2004 in a specifically designed database for retrospective analysis. Invasive aspergillosis was defined according to the European Organization for Research and Treatment of Cancer classifications. Univariate analysis and logistic regression were performed to assess the influence of each assumed risk factor.
resultsA total of 195 liver transplantations were performed in 170 patients, with two patients (1.2%) developing a proven IA, seven (4.1%) developing a probable IA, and five developing a possible IA (2.9%). All patients received oral itraconazole prophylaxis. Of these 14 patients with proven, probable or possible IA, 13 died within 4 weeks after the initial diagnosis; this represents 33.3% of all patients with a fatal outcome. Univariate significant factors were retransplantation (p = 0.004), cytomegalovirus (CMV) infection (p = 0.024), dialysis (p < 0.001), renal insufficiency (p = 0.05), thrombocytopenia (p = 0.001), and leukocytopenia (p = 0.002). Multivariate analysis showed an independent influence of CMV infection (OR 6.032, 95% CI 1.446-25.163) and dialysis (OR 14.985, 95%CI 2.936-76.486).
conclusionThe rate of IA found in this investigation is within the range reported in published studies. Based on our data, extended antifungal prophylaxis should be given to liver transplant patients with specific risk factors, such as renal insufficiency, requirement for dialysis, CMV infection, or thrombocytopenia. Additional focus should be on the prevention of CMV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.